Clinical trials: Allogeneic Stem-Cell Transplant
Hodgkin's Disease
Allogeneic Blood Stem Cell Transplantation
1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2.
- Trial name
- NCT00423709
- Testing
- Allogeneic Blood Stem Cell Transplantation, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Acute GVHD
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
- Trial name
- NCT03701698
- Testing
- Ruxolitinib Oral Tablet, Methylprednisolone
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematopietic Stem Cell Transplantation, Blood Virome
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients
The Geneva Blood Virome Project is a longitudinal observational study. The main objective is to describe the kinetics of the plasmatic viral load of a selection of at least 21 DNA and RNA viruses of the blood virome in allogeneic…
- Conditions
- Hematopietic Stem Cell Transplantation, Blood Virome, RNA Virus Infections, DNA Virus Infections
- Trial name
- GeBVir (NCT03642977)
- Testing
- Real time PCR and RT-PCR for DNA and RNA viral species
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Geneva
Leukemia, Myeloid, Leukemia, Lymphocytic
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers…
- Conditions
- Leukemia, Myeloid, Leukemia, Lymphocytic, Myelodysplastic Syndrome, Leukemia, Myeloid, Chronic
- Trial name
- NCT00306332
- Testing
- T-cell and B-cell depletion
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- Radboud University Medical Center
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cytomegalovirus Infections
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
Patients have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- VICTA (NCT00078533)
- Testing
- CMV CTL infusion
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Sickle Cell Disease, Beta Thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease.
- Trial name
- NCT00408447
- Testing
- Busulfan, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Graft Versus Host Disease, Leukemia
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00423514
- Testing
- filgrastim, clofarabine, melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic Stem Cell Transplantation
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
The protocols including ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF) have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation from…
- Trial name
- NCT04203108
- Testing
- ATG, CsA, MTX
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia…
- Trial name
- NCT07250087
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
I Cell Disease, Fucosidosis
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation (HSCT) for the presence of proinflammatory…
- Conditions
- I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy
- Trial name
- NCT00005900
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Graft Versus Host Disease, Hematological Malignancies
T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.
This study evaluates the frequency of occurrence, severity, and response to treatment by a chemical agent, notably the dimerizer AP1903 (Bellicum Pharmaceuticals compagny), in the case of acute Graft versus Host Disease (aGvHD)…
- Trial name
- Side_by_Cide (NCT02849886)
- Testing
- T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT04713956
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU)
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Sickle Cell Disease, Thalassemia
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who…
- Conditions
- Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy
- Trial name
- NCT03367546
- Testing
- Blood and Marrow Transplant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Myelofibrosis
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might…
- Trial name
- HOVON134MF (NCT03645824)
- Testing
- Pacritinib
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 61 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
CMV Infection
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant…
- Trial name
- CY-CMV-2020 (NCT05315882)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.
- Trial name
- EPRALLO (NCT02577094)
- Testing
- 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG, Busulfan, allogeneic stem cell transplantation.
- Sponsor
- Nantes University Hospital
Stem Cell Transplantation, Graft Vs Host Disease
Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation
Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications.
- Trial name
- NCT00130754
- Testing
- Thymoglobuline
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.